Gilead Sciences' oral hepatitis C drug Sovaldi has taken the market by storm, but Merck's looking to fight back in the race to capture this lucrative niche.
Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.
A better interface won't mean much if Google’s Android TV bet doesn't also include big infrastructure investments.
Amazon has expanded into numerous new markets in the last five years, but is that creating any value for shareholders?
Word has it the social-media giant is looking to Ireland to test a new money-transfer service. That's nice, but will always be ancillary to its core business.
Is the plummeting valuation justified?
This Texas-based biotech reported positive proof-of-concept results earlier this week and could be set to upend a number of big pharmaceutical companies if its experimental drug continues to deliver.
Long-term thinking creates short-term opportunity for investors looking at Apple, Baidu, and MercadoLibre.
Foreign exchange markets have been placid overall, and trading returns are dropping. Is this the new normal, or is a correction imminent?
Here's a second chance to invest in companies with viable growth potential.